Eli Lilly and Company

LLY

Drug Manufacturers - General · Healthcare

Price

$1179.09

+9.92 (+0.85%)

Market Cap

$1.11T

Winston Score

Winston is happy

A high-quality business with solid fundamentals.

Share count falling — buybacks

−5.8% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 953.7M (2021) → 898.0M (2025)

Eli Lilly is a large pharmaceutical company that discovers, makes, and sells prescription medicines. Its biggest products right now are Mounjaro and Zepbound for diabetes and weight loss, plus Verzenio for breast cancer and Jardiance for diabetes. Doctors and hospitals are the main customers, and patients use these drugs to treat serious chronic conditions.

Lilly makes money by selling branded prescription drugs, mostly at high prices protected by patents. It operates globally, with a large share of revenue coming from the United States, and it is one of the largest drug companies in the world by market value. Its main competitive advantage is its patent-protected drug portfolio and a strong pipeline of new medicines in development. The biggest growth driver is demand for its GLP-1 weight-loss and diabetes drugs, which has been enormous, but the main risk is that patents eventually expire, opening the door to cheaper generic competition.

Winston Score History

Politician Trades

42 trades / 12mo

23 Congressional buys and 19 sells on LLY in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+42.6% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+50.9% YoY

YoY Growth Rate

Strong earnings growth

R&D Spend

$13.3B/ year

↑ Rising (+21% vs prior year)

20.5% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

10.1%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$7.2B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Revenue accelerating

Eli Lilly and Company grew revenue 43% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

85.1%

Premium pricing power — 85.1% gross margin

Operating Margin

45.5%

Excellent — 45.5% operating margin

ROCE

12.7%

Good — 12.7% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+44.7%

Fast-growing sales (44.7% YoY)

EPS YoY

+95.4%

Earnings growing fast (95.4% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

81%

Modest — 81% of profit becomes cash

FCF Margin

13.8%

Converts sales into free cash efficiently (13.8%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

1.60

Elevated debt (1.60)

Interest Cover

37.34x

Comfortably covers interest (37.3x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

51.3x

Expensive — P/E 51.3

P/E over 35. The market is pricing in heavy, sustained growth.

P/E vs Forward

+27.8

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (51.3 → 23.5)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield

0.54%

Small dividend — 0.54% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend Growth

+15.3%

Dividend growing fast (15.3% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial